Journal article
A Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD): a Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAs
Abstract
METHODS: We conducted a multinational pharmacoeconomic evaluation comparing the immediate release form of a new class of serotonin norepinephrine reuptake inhibitor (SNRI), venlafaxine IR to the selective serotonin reuptake inhibitors (SSRIs) and the tricyclic antidepressants (TCAs) in the treatment of acute major depressive disorder (MDD) in 10 countries (Germany, Italy, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom, United …
Authors
Doyle JJ; Casciano J; Arikian S; Tarride J-E; Gonzalez MA; Casciano R
Journal
Value in Health, Vol. 4, No. 1, pp. 16–31
Publisher
Elsevier
Publication Date
January 2001
DOI
10.1046/j.1524-4733.2001.004001016.x
ISSN
1098-3015
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Antidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicBudgetsCost-Benefit AnalysisCyclohexanolsDecision TreesDepressive Disorder, MajorDrug CostsEconomics, PharmaceuticalEuropeHealth Services ResearchHumansInsurance, Health, ReimbursementMonte Carlo MethodSelective Serotonin Reuptake InhibitorsUnited StatesVenezuelaVenlafaxine Hydrochloride